The long-term goal of this research is to understand the role of syt-ssx gene product in synovial sarcoma pathogenesis, and to develop novel and effective treatment for the disease. The cause of synovial sarcoma is unknown. However, a characteristic fusion of two genes, syt and ssx, has been identified. We have recently discovered a peptide that blocks SYT function in vitro. Based on the finding, I propose to further determine if this peptide is able to target SYT-SSX and block its activities in vivo. This may eventually lead to the discovery of novel treatment for synovial sarcoma.
Yuechueng Liu, PhD, University of Oklahoma Health Sciences Center
Recipient of the: $25,000 Paul M. Rumely Memorial Research Award